AR096748A1 - Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina - Google Patents

Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina

Info

Publication number
AR096748A1
AR096748A1 ARP140102420A ARP140102420A AR096748A1 AR 096748 A1 AR096748 A1 AR 096748A1 AR P140102420 A ARP140102420 A AR P140102420A AR P140102420 A ARP140102420 A AR P140102420A AR 096748 A1 AR096748 A1 AR 096748A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
group
haloalkyl
independently selected
Prior art date
Application number
ARP140102420A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51205521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR096748(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AR096748A1 publication Critical patent/AR096748A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos útiles para utilizar como medicamentos para controlar trastornos psiquiátricos y neurológicos, y sales farmacéuticamente aceptables de los mismos; procesos como la preparación de intermediarios utilizados en la preparación de; y composiciones que contienen los compuestos o sales, y su usos para tratar los trastornos mediados por D1 (o asociados con D1) que incluyen, por ejemplo, esquizofrenia (por ejemplo, sus síntomas cognitivos y negativos), discapacidad cognitiva (por ejemplo, discapacidad cognitiva asociada con esquizofrenia, AD, PD, o terapia de farmacoterapia), declive cognitivo relacionado con la edad, demencia y enfermedad de Parkinson. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: cada uno de T¹, T², T³, y T⁴ se selecciona independientemente del grupo que consiste de H, halógeno, -CN, -SF₅, -OH, -N(Rᵃ)(Rᵇ), -C(=O)-N(Rᵃ)(Rᵇ), -C(=O)-ORᶜ, -C(=O)-Rᵈ, alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, -S-(alquilo C₁₋₆), cicloalquilo C₃₋₇, heterocicloalquilo de 4 a 7 miembros, cicloalcoxi C₃₋₇ heteroarilo de 5 ó 6 miembros, ciclopropilmetilo, y ciclobutilmetilo, en donde cada uno del alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, -S-(alquilo C₁₋₆), y alcoxi C₁₋₆ se sustituye opcionalmente con uno o más sustituyentes cada uno seleccionado independientemente del grupo que consiste de halógeno, -OH, -CN, -N(Rᵃ)(Rᵇ), alcoxi C₁₋₄, haloalcoxi C₁₋₄, y -S-(alquilo C₁₋₄); y en donde cada uno del cicloalquilo C₃₋₇, heterocicloalquilo de 4 a 7 miembros, cicloalcoxi C₃₋₇, heteroarilo de 5 ó 6 miembros, ciclopropilmetilo, y ciclobutilmetilo de T¹, T², y T³ se sustituye opcionalmente con uno o más sustituyentes cada uno es seleccionado independientemente del grupo que consiste de halógeno, -OH, -CN, oxo, -N(Rᵃ)(Rᵇ), -C(=O)OH, -C(=O)-alquilo C₁₋₄, -C(=O)-O-alquilo C₁₋₄, -C(=O)-N(Rᵃ)(Rᵇ), alquilo C₁₋₄, haloalquilo C₁₋₄, hidroxilalquilo C₁₋₄, cianoalquilo C₁₋₄, alcoxi C₁₋₄, haloalcoxi C₁₋₄, y -S-(alquilo C₁₋₄); L¹ se selecciona del grupo que consiste de O, S, NH, N(alquilo C₁₋₄), N(-alquilo C₁₋₂-cicloalquilo C₃₋₄), y N(cicloalquilo C₃₋₆); cada uno de Rᵃ y Rᵇ se selección independientemente del grupo que consiste de H, alquilo C₁₋₄, cicloalquilo C₃₋₇, y ciclopropilmetilo; o Rᵃ y Rᵇ junto con el átomo N al cual se unen forman heterocicloalquilo de 4 a 7 miembros opcionalmente sustituido con uno o más sustituyentes cada uno seleccionado independientemente del grupo que consiste de halógeno, -OH, -CN, oxo, -NH₂, -NH(alquilo C₁₋₄), -N(alquilo C₁₋₄)₂, -C(=O)OH, -C(=O)-alquilo C₁₋₄, -C(=O)-O-alquilo C₁₋₄, -C(=O)-NH₂, -C(=O)-NH(alquilo C₁₋₄), -C(=O)-N(alquilo C₁₋₄)₂, alquilo C₁₋₄, haloalquilo C₁₋₄, hidroxilalquilo C₁₋₄, cianoalquilo C₁₋₄, alcoxi C₁₋₄, -S-(alquilo C₁₋₄), y haloalcoxi C₁₋₄; cada uno de Rᶜ y Rᵈ es independientemente alquilo C₁₋₄, cicloalquilo C₃₋₄-alquilo C₁₋₂-, o cicloalquilo C₃₋₄; Q¹ se selecciona del grupo que consiste de Q¹ᵃ, Q¹ᵇ, Q¹ᶜ, Q¹ᵈ y Q¹ᵉ del grupo de fórmulas (2); condición de (a) que un átomo de carbono del anillo Q¹ se encuentre unido al anillo benceno de la fórmula (1) y (b) que cuando L¹ es NH, entonces el anillo Q¹ se sustituya con al menos uno que no sea H R⁹, R¹⁰, R¹¹, R¹², R¹³, R⁹A, R¹⁰A, R¹⁰B, R¹¹A, R¹²A ó R¹³A; cada uno de X¹ y X² es independientemente O ó S; cada uno de R¹, R², R³, y R⁴ se selecciona independientemente del grupo que consiste de H, halógeno, -OH, -NO₂, -CN, -SF₅, alquilo C₁₋₆, haloalquilo C₁₋₆ haloalcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 a 10 miembros, -N(R⁵)(R⁶), -N(R⁷)(C(=O)R⁸), -C(=O)-(R⁵)(R⁶), -C(=O)-R⁸, -C(=O)-OR⁸, -N(R⁷)(S(=O)₂R⁸), -S(=O)₂-N(R⁵)(R⁶), -SR⁸, y -OR⁸, en donde cada uno del alquilo C₁₋₆, cicloalquilo C₃₋₇, y heterocicloalquilo se sustituye opcionalmente con 1, 2, ó 3 sustituyentes cada uno seleccionado independientemente del grupo que consiste de halógeno, -CN, oxo, -OH, alquilo C₁₋₄, alcoxi C₁₋₄, haloalquilo C₁₋₄, haloalcoxi C₁₋₄, cicloalquilo C₃₋₆, -N(R⁵)(R⁶), -N(R⁷)(C(=O)R⁸), -C(=O)-OR⁸, -C(=O)H, -C(=O)R⁸, -C(=O)N(R⁵)(R⁶), -N(R⁷)(S(=O)₂R⁸), -S(=O)₂-N(R⁵)(R⁶), -SR⁸, y -OR⁸; o R² y R⁴ junto con los dos átomos al cual se unen forman un heteroarilo fusionado de 5 ó 6 miembros, un anillo heterocicloalquilo fusionado de 5 ó 6 miembros, un anillo cicloalquilo fusionado de 5 ó 6 miembros, o un anillo benceno fusionado, en donde cada uno de los anillos fusionados se sustituye opcionalmente con 1, 2, ó 3 sustituyentes cada uno seleccionado independientemente del grupo que consiste de halo, -CN, -OH, alquilo C₁₋₄, alcoxi C₁₋₄, haloalquilo C₁₋₄, y haloalcoxi C₁₋₄, y en donde el anillo heterocicloalquilo fusionado o anillo cicloalquilo fusionado además se sustituye opcionalmente con 1, 2, ó 3 oxo; R⁵ es H, alquilo C₁₋₄, haloalquilo C₁₋₄, o cicloalquilo C₃₋₇; R⁶ es H o se selecciona del grupo que consiste de alquilo C₁₋₄, haloalquilo C₁₋₄, cicloalquilo C₃₋₇, heterocicloalquilo de 4 a 10 miembros, arilo C₆₋₁₀, un heteroarilo de 5 a 10 miembros, (cicloalquilo C₃₋₇)-alquilo C₁₋₄-, (heterocicloalquilo de 4 a 10 miembros)-alquilo C₁₋₄-, (arilo C₆₋₁₀)-alquilo C₁₋₄-, y (heteroarilo de 5 a 10 miembros)-alquilo C₁₋₄-, en donde cada uno se selecciona del grupo que se sustituye opcionalmente con 1, 2, 3, ó 4 sustituyentes cada uno seleccionado independientemente del grupo que consiste de -OH, -CN, alquilo C₁₋₄, cicloalquilo C₃₋₇, hidroxilalquilo C₁₋₄, -S-alquilo C₁₋₄, -C(=O)H, -C(=O)-alquilo C₁₋₄, -C(=O)-O-alquilo C₁₋₄, -C(=O)-NH₂, -C(=O)-N(alquilo C₁₋₄)₂, haloalquilo C₁₋₄, alcoxi C₁₋₄, y haloalcoxi C₁₋₄; o R⁵ y R⁶ junto con el átomo N al cual se unen forman heterocicloalquilo de 4 a 10 miembros o un heteroarilo de 5 a 10 miembros, cada uno opcionalmente sustituido con 1, 2, 3, 4, ó 5 sustituyentes cada uno seleccionado independientemente del grupo que consiste de halógeno, -OH, oxo, -C(=O)H, -C(=O)-alquilo C₁₋₄, -C(=O)OH, -C(=O)-O-alquilo C₁₋₄, -C(=O)-NH₂, -C(=O)-N(alquilo C₁₋₄)₂, -CN, alquilo C₁₋₄, alcoxi C₁₋₄, hidroxilalquilo C₁₋₄, haloalquilo C₁₋₄, y haloalcoxi C₁₋₄; R⁷ se selecciona del grupo que consiste de H, alquilo C₁₋₄, y cicloalquilo C₃₋₇; R⁸ se selecciona del grupo que consiste de alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo de 4 a 10 miembros, arilo C₁₋₆, un heteroarilo de 5 a 10 miembros, (cicloalquilo C₃₋₄)-alquilo C₁₋₄-, (heterocicloalquilo de 4 a 10 miembros)-alquilo C₁₋₄-, (arilo C₆₋₁₀)-alquilo C₁₋₄-, y (heteroarilo de 5 a 10 miembros)-alquilo C₁₋₄-, en donde cada uno se selecciona del grupo que se sustituye opcionalmente con 1, 2, ó 3 sustituyentes cada uno seleccionado independientemente del grupo que consiste de halógeno, -CF₃, -CN, -OH, oxo, -S-alquilo C₁₋₄, alquilo C₁₋₄, haloalquilo C₁₋₄, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₇, alcoxi C₁₋₄, y haloalcoxi C₁₋₄; cada R⁹ y R¹² se selecciona independientemente del grupo que consiste de halógeno, -OH, -CN, -SF₅,
ARP140102420A 2013-06-27 2014-06-26 Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina AR096748A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361840144P 2013-06-27 2013-06-27

Publications (1)

Publication Number Publication Date
AR096748A1 true AR096748A1 (es) 2016-02-03

Family

ID=51205521

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102420A AR096748A1 (es) 2013-06-27 2014-06-26 Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina

Country Status (42)

Country Link
US (10) US9527831B2 (es)
EP (2) EP3421462B1 (es)
JP (1) JP6026024B2 (es)
KR (1) KR101781723B1 (es)
CN (1) CN105324376B (es)
AP (1) AP2015008844A0 (es)
AR (1) AR096748A1 (es)
AU (1) AU2014300673B2 (es)
BR (1) BR122023004130B1 (es)
CA (1) CA2916653C (es)
CL (1) CL2015003735A1 (es)
CR (1) CR20150634A (es)
CU (1) CU24334B1 (es)
DK (2) DK3421462T3 (es)
DO (1) DOP2015000302A (es)
EA (1) EA028637B1 (es)
EC (1) ECSP16003103A (es)
ES (2) ES2948192T3 (es)
FI (1) FI3421462T3 (es)
GT (1) GT201500350A (es)
HK (1) HK1215435A1 (es)
HR (2) HRP20230546T1 (es)
HU (2) HUE062265T2 (es)
IL (1) IL242480B (es)
MA (1) MA38661A1 (es)
MD (1) MD20150122A2 (es)
MX (2) MX2015017169A (es)
NI (1) NI201500179A (es)
NZ (1) NZ713762A (es)
PE (1) PE20160664A1 (es)
PH (1) PH12015502502A1 (es)
PL (2) PL3421462T3 (es)
PT (2) PT3421462T (es)
RS (2) RS64342B1 (es)
SG (1) SG11201509186TA (es)
TN (1) TN2015000547A1 (es)
TR (1) TR201907981T4 (es)
TW (1) TWI508957B (es)
UA (1) UA112945C2 (es)
UY (1) UY35628A (es)
WO (1) WO2014207601A1 (es)
ZA (1) ZA201508252B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323821A1 (en) 2012-11-08 2018-05-23 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
WO2014207601A1 (en) 2013-06-27 2014-12-31 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
BR112016023740A2 (pt) 2014-04-25 2017-08-15 Pfizer compostos heteroaromáticos e seu uso como ligantes de dopamina d1
CA2946471C (en) 2014-04-25 2018-08-07 Pfizer Inc. Fused bicyclic heteroaromatic compounds and their use as dopamine d1 ligands
EP3137469B1 (en) 2014-04-28 2019-10-09 Pfizer Inc Heterocyclic compounds and their use as dopamine d1 ligands
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CN111153859B (zh) * 2015-04-15 2021-09-03 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
BR112018007395A2 (pt) 2015-10-14 2018-10-23 Bristol-Myers Squibb Company 2,4-di-hidróxi-nicotinamidas como agonistas de apj
ES2820823T3 (es) 2015-12-18 2021-04-22 Janssen Pharmaceutica Nv Ligandos PET mGluR2/3 radiomarcados
AU2016374571B2 (en) 2015-12-18 2021-05-06 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
ES2837018T3 (es) * 2016-01-15 2021-06-29 Pfizer Ligandos del receptor D3 de dopamina de 6,7,8,9-tetrahidro-5H-pirido[2,3-d]azepina
BR112018068341A2 (pt) 2016-03-24 2019-01-15 Bristol-Myers Squibb Company 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
CN108884055B (zh) 2016-03-30 2022-07-12 石原产业株式会社 哒嗪酮系化合物或其盐、以及含有它们的除草剂
WO2018157843A1 (zh) * 2017-03-02 2018-09-07 中国科学院上海药物研究所 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
JP2023522949A (ja) * 2020-04-23 2023-06-01 オプナ バイオ ソシエテ アノニム Ｃｄ７３調節のための化合物及び方法並びにそれらの表示
EP4441039A1 (en) 2021-12-03 2024-10-09 Teva Czech Industries s.r.o Solid state forms of tavapadon and processes for preparation thereof
WO2023143321A1 (zh) * 2022-01-29 2023-08-03 苏州科睿思制药有限公司 他伐帕敦的晶型及其制备方法和用途

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5025142B1 (es) 1969-07-30 1975-08-21
JPS5039272B1 (es) 1970-07-14 1975-12-16
JPS5025142A (es) 1973-07-06 1975-03-17
JPS5039272A (es) 1973-08-10 1975-04-11
JPS5516432B2 (es) 1974-05-28 1980-05-01
JPS51113899A (en) 1975-03-27 1976-10-07 Yoshitomi Pharmaceut Ind Ltd Method for preparing novel tetrazole derivatives
JPS522031A (en) 1975-06-24 1977-01-08 Japan Niyuupureito Hokushiyou Sunshade device
DE2861615D1 (en) 1978-01-02 1982-03-11 Ciba Geigy Ag Phenoxy-alkyl oxazolines, their preparation, compositions containing them and their application as herbicides
EP0101662A3 (de) 1982-06-25 1985-12-04 Ciba-Geigy Ag Benzoylparabansäuren
US4550108A (en) 1983-08-17 1985-10-29 Ciba Geigy Corporation 1,3,5-Oxadiazine-2,4-diones and pesticidal use
US4723015A (en) 1983-10-17 1988-02-02 Ciba-Geigy Corporation Certain insecticidal N-2-pyridyloxyphenylbenzimidates
IL73611A0 (en) 1983-12-06 1985-02-28 Nippon Soda Co 1,2,4-oxa-and thiadiazolin-3-one derivatives,their preparation and their use as insecticides and fungicides
JPS61275271A (ja) 1985-05-30 1986-12-05 Nippon Soda Co Ltd １，２，４−オキサ（チア）ジアゾリン誘導体、その製造方法，殺虫剤及び農園芸用殺菌剤
DE3545569A1 (de) 1985-12-21 1987-06-25 Hoechst Ag Neue pyridin-derivate, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als schaedlingsbekaempfungsmittel
DE3545786A1 (de) 1985-12-21 1987-06-25 Schering Ag Pyrazolinderivate, ihre herstellung und ihre verwendung als mittel mit insektizider wirkung
DE3631511A1 (de) 1986-09-12 1988-03-24 Schering Ag 5-halogen-1,2,4-triazole, verfahren zu ihrer herstellung und ihre verwendung als akarizide und insektizide mittel
EP0296518A1 (de) 1987-06-22 1988-12-28 Ciba-Geigy Ag Neue Phenylether-derivate als Mikrobizide, Verfahren zu deren Herstellung und deren Verwendung
DE3826855A1 (de) * 1988-08-06 1990-02-15 Cassella Ag 4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung
JPH0259574A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ピラジノン誘導体又はその塩類
JPH0259573A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ２（１ｈ）−ピリミジノン誘導体又はその塩類
US5066667A (en) 1989-06-26 1991-11-19 Ciba-Geigy Corporation Thioxotetrazolines and insecticidal use thereof
DE69104071T2 (de) 1990-01-18 1995-05-11 Nissan Chemical Ind Ltd Uracilderivate und Pestizide, die diese als wirksame Stoffe enthalten.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH03261783A (ja) 1990-03-12 1991-11-21 Suntory Ltd １，２，４―トリアジンジオン化合物及びそれを有効成分とする抗コクシジウム剤
DE4030042A1 (de) 1990-05-17 1991-11-21 Bayer Ag Verwendung von substituierten 1,2,4-triazindionen
JP3018422B2 (ja) 1990-07-27 2000-03-13 日東紡績株式会社 床 材
US5630962A (en) 1990-12-19 1997-05-20 Hoechst Aktiengesellschaft 2-Fluoropyridines, their preparation and their use in liquid crystal mixtures
JPH0539272A (ja) 1991-01-09 1993-02-19 Nissan Chem Ind Ltd ピリミジンジオン誘導体および除草剤
JPH0525142A (ja) 1991-07-12 1993-02-02 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
JPH05202031A (ja) 1992-01-28 1993-08-10 Nissan Chem Ind Ltd Ｎ−アミノピリミジンジオン誘導体および除草剤
WO1993018016A1 (en) 1992-03-11 1993-09-16 E.I. Du Pont De Nemours And Company Fungicidal oxazolidinones
US5482951A (en) 1992-05-29 1996-01-09 Kumiai Chemical Industry Co., Ltd. Triazole derivatives as well as insecticide and acaricide
EP0612320A1 (en) 1992-08-31 1994-08-31 Ciba-Geigy Ag 4,5-dicyanoimidazole derivatives and pesticidal compositions containing them
AU673881B2 (en) 1992-12-25 1996-11-28 Nippon Soda Co., Ltd. Heterocyclic derivative and pest control agent
JP3261783B2 (ja) 1993-02-04 2002-03-04 ミノルタ株式会社 光変調素子
JP3682075B2 (ja) 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
WO1995004724A1 (fr) 1993-08-11 1995-02-16 Nippon Soda Co., Ltd. Derive d'imidazole et son procede de production, et substance anti-nuisibles
JPH0873446A (ja) 1994-04-22 1996-03-19 Nippon Soda Co Ltd ヘテロ環化合物および殺虫・殺ダニ剤
JPH0827120A (ja) 1994-07-08 1996-01-30 Nissan Chem Ind Ltd テトラヒドロピリミジノン誘導体
JPH08217777A (ja) 1995-02-10 1996-08-27 Nippon Nohyaku Co Ltd ２−ピラゾリン−５−オン誘導体及びその中間体並びに除草剤
DE19518681A1 (de) 1995-05-22 1996-11-28 Bayer Ag Verfahren zur Herstellung von 5,6-Dihydro-1,3-oxazinen
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JPH09291282A (ja) 1996-04-26 1997-11-11 Sumitomo Chem Co Ltd 安定化した液晶材料およびこれを用いた液晶素子
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6355799B1 (en) * 1997-10-27 2002-03-12 Isk Americas Incorporated Substituted benzene compounds, process for their preparation, and herbicidal and defoliant compositions containing them
US6521641B1 (en) 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
WO2000024735A1 (en) 1998-10-23 2000-05-04 Dow Agrosciences Llc Insecticidal 1-(substituted pyridyl)-1,2,4-triazoles
GB9903671D0 (en) 1999-02-17 1999-04-14 Cenes Ltd Dopamine D-1 receptor agonist compounds
BR0107662A (pt) 2000-01-18 2002-11-19 Pfizer Prod Inc Antagonistas do fator de liberação de corticotropina
JP3831253B2 (ja) 2000-04-04 2006-10-11 塩野義製薬株式会社 高脂溶性化合物を含有する油性組成物
CA2409762A1 (en) 2000-06-23 2002-01-03 Donald J.P. Pinto Heteroaryl-phenyl substituted factor xa inhibitors
US6476055B1 (en) 2001-03-28 2002-11-05 Nippon Soda Co. Ltd. 5,5-disubstituted thiazolidine derivative pesticides
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
EP1386915A4 (en) 2001-05-09 2004-11-10 Sumitomo Chem Takeda Agro Co AZOLE-LIKE COMPOUNDS, PROCESS FOR THE PREPARATION AND USE OF SAID COMPOUNDS
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
ES2421511T3 (es) 2001-12-21 2013-09-03 X Ceptor Therapeutics Inc Moduladores de LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003079986A2 (en) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
WO2004018410A1 (ja) 2002-08-26 2004-03-04 Nissan Chemical Industries, Ltd. 置換ベンズアニリド化合物及び有害生物防除剤
AU2003276201A1 (en) 2002-11-11 2004-06-03 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
US6969744B2 (en) 2003-06-19 2005-11-29 University Of Southern Mississippi Living and quasiliving cationic telechelic polymers quenched by N-substituted pyrrole and methods for their preparation
EA009201B1 (ru) 2003-09-03 2007-12-28 Пфайзер Инк. Фенил - или пиридиламидные соединения в качестве антагонистов простагландина e2
JP4451849B2 (ja) 2003-11-28 2010-04-14 日本曹達株式会社 アリール複素環誘導体および農園芸用殺菌剤および殺虫剤
JP2005272452A (ja) 2004-02-23 2005-10-06 Nissan Chem Ind Ltd 置換ベンズアニリド化合物及び有害生物防除剤
JP2007533723A (ja) 2004-04-20 2007-11-22 ファイザー・プロダクツ・インク α２δリガンドを含む組合せ
WO2005113494A2 (en) 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
TW200612827A (en) 2004-08-25 2006-05-01 Sumitomo Chemical Co Insecticide composition
ES2396365T3 (es) * 2005-07-29 2013-02-21 Concert Pharmaceuticals Inc. Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
GB0524786D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
CA2641766A1 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP5025142B2 (ja) 2006-02-27 2012-09-12 株式会社東芝 モータ制御装置
BRPI0708731A2 (pt) 2006-03-10 2011-06-07 Ono Pharmaceutical Co derivado heterocìclico nitrogenado, e agente farmacêutico compreendendo o derivado como ingrediente ativo
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2007124546A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors 3
PT2094663E (pt) 2006-09-21 2011-04-19 Piramal Life Sciences Ltd Derivados de piridina para o tratamento de desordens metabólicas relacionadas com resistência à insulina ou hiperglicemia
EP2256496A3 (en) 2006-09-21 2011-03-16 Piramal Life Sciences Limited Method for identifying compounds that act as insulin-sensitizers
RU2478635C2 (ru) 2006-10-19 2013-04-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
EP1916240A1 (en) * 2006-10-25 2008-04-30 Syngeta Participations AG Pyridazine derivatives
DE102007003036A1 (de) 2006-12-20 2008-06-26 Bayer Cropscience Ag Pyrimidinylpyrazole
WO2008094909A2 (en) 2007-01-29 2008-08-07 Xenon Pharmaceuticals Inc. Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
JP2010519267A (ja) 2007-02-22 2010-06-03 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 新規殺微生物剤
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
AR065622A1 (es) 2007-03-07 2009-06-17 Ortho Mcneil Janssen Pharm Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CN101294257B (zh) 2007-04-23 2014-06-18 株式会社神户制钢所 焊接热影响部的韧性优异的钢材及其制造方法
JP2009062290A (ja) 2007-09-04 2009-03-26 Takeda Chem Ind Ltd シクロプロパン化合物
EA019085B1 (ru) * 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
EP2203426B9 (en) 2007-10-31 2013-02-13 Abbott GmbH & Co. KG Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110071197A1 (en) 2008-04-16 2011-03-24 Peter Nilsson Bis-aryl compounds for use as medicaments
US20110112193A1 (en) 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
CN102131801B (zh) 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
CA2736970A1 (en) * 2008-09-12 2010-03-18 Biolipox Ab Pyrimidinone derivatives for use as medicaments
WO2010064688A1 (ja) 2008-12-03 2010-06-10 日本農薬株式会社 ピリミジン誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法
WO2010068788A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
PE20142099A1 (es) 2009-01-12 2014-12-13 Icagen Inc Derivados de sulfonamida
EP2246335A1 (de) 2009-02-17 2010-11-03 Bayer CropScience AG Aminopyrimidinamide als Schädlingsbekämpfungsmittel
AU2011223888B2 (en) * 2010-03-04 2015-07-02 Merck Sharp & Dohme Llc Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
CA2812043A1 (en) 2010-04-23 2011-10-27 Kineta, Inc. Pyrimidinedione anti-viral compounds
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
WO2012020848A1 (en) 2010-08-10 2012-02-16 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9056832B2 (en) 2010-09-17 2015-06-16 Purdue Pharma L.P. Pyridine compounds and the users thereof
PL2753606T3 (pl) * 2011-09-02 2018-02-28 Purdue Pharma L.P. Pirymidyny jako blokery kanałów sodowych
EP3323821A1 (en) * 2012-11-08 2018-05-23 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
GEP201606598B (en) * 2012-11-08 2017-01-10 Pfizer Heteroaromatic compounds as dopamine d1 ligands
WO2014119770A1 (ja) * 2013-01-30 2014-08-07 住友化学株式会社 ピリダジノン化合物及びそれを含有する除草剤
WO2014207601A1 (en) * 2013-06-27 2014-12-31 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Also Published As

Publication number Publication date
ZA201508252B (en) 2019-04-24
HUE062265T2 (hu) 2023-10-28
EP3421462A1 (en) 2019-01-02
US10093655B2 (en) 2018-10-09
PT3421462T (pt) 2023-06-29
EA028637B1 (ru) 2017-12-29
US20150196561A1 (en) 2015-07-16
IL242480A0 (en) 2016-02-01
EP3013813B1 (en) 2019-04-03
IL242480B (en) 2019-09-26
EA201592146A1 (ru) 2016-05-31
US9139561B2 (en) 2015-09-22
PT3013813T (pt) 2019-06-14
ES2948192T3 (es) 2023-09-01
HUE043705T2 (hu) 2019-09-30
NI201500179A (es) 2016-02-11
DK3421462T3 (da) 2023-06-12
TWI508957B (zh) 2015-11-21
US20190367485A1 (en) 2019-12-05
CU24334B1 (es) 2018-04-03
SG11201509186TA (en) 2016-01-28
PL3013813T3 (pl) 2019-10-31
CR20150634A (es) 2016-01-04
TW201512185A (zh) 2015-04-01
CL2015003735A1 (es) 2016-06-24
US9527831B2 (en) 2016-12-27
US10421744B2 (en) 2019-09-24
PE20160664A1 (es) 2016-07-09
JP6026024B2 (ja) 2016-11-16
HRP20230546T1 (hr) 2023-08-04
US9822097B2 (en) 2017-11-21
MD20150122A2 (ro) 2016-05-31
US20150005313A1 (en) 2015-01-01
CA2916653C (en) 2017-07-18
GT201500350A (es) 2017-09-28
RS59018B1 (sr) 2019-08-30
CA2916653A1 (en) 2014-12-31
RS64342B1 (sr) 2023-08-31
BR112015030101A2 (pt) 2017-07-25
UY35628A (es) 2015-01-30
US20170057947A1 (en) 2017-03-02
HRP20191163T1 (hr) 2019-10-04
US20200283407A1 (en) 2020-09-10
CN105324376B (zh) 2017-06-23
NZ713762A (en) 2018-03-23
CN105324376A (zh) 2016-02-10
WO2014207601A1 (en) 2014-12-31
EP3421462B1 (en) 2023-04-05
US20190002439A1 (en) 2019-01-03
HK1215435A1 (zh) 2016-08-26
PH12015502502A1 (en) 2016-02-22
DK3013813T3 (da) 2019-06-03
MA38661A1 (fr) 2017-03-31
MX2020013099A (es) 2022-07-26
EP3013813A1 (en) 2016-05-04
US11964961B2 (en) 2024-04-23
TR201907981T4 (tr) 2019-06-21
ECSP16003103A (es) 2017-08-31
US20180037571A1 (en) 2018-02-08
UA112945C2 (uk) 2016-11-10
JP2016531083A (ja) 2016-10-06
US20210300899A1 (en) 2021-09-30
AU2014300673A1 (en) 2015-11-12
BR122023004130B1 (pt) 2023-12-12
US10696658B2 (en) 2020-06-30
KR101781723B1 (ko) 2017-10-23
DOP2015000302A (es) 2016-02-29
MX2015017169A (es) 2016-04-06
US20240317713A1 (en) 2024-09-26
US11014909B2 (en) 2021-05-25
AP2015008844A0 (en) 2015-11-30
US20150175573A1 (en) 2015-06-25
AU2014300673B2 (en) 2017-12-14
ES2729630T3 (es) 2019-11-05
FI3421462T3 (fi) 2023-06-26
TN2015000547A1 (fr) 2017-04-06
KR20160014665A (ko) 2016-02-11
PL3421462T3 (pl) 2023-09-11
US9107923B2 (en) 2015-08-18
CU20150180A7 (es) 2016-05-30

Similar Documents

Publication Publication Date Title
AR096748A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR109788A1 (es) Compuestos de benzo[b]tiofeno como agonistas de sting
AR100691A1 (es) Esteroides neuroactivos, composiciones, y usos de los mismos
AR088327A1 (es) Agentes inductores de la apoptosis para tratar el cancer y las enfermedades inmunes y autoinmunes
AR103297A1 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
AR108012A1 (es) Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR102492A1 (es) Cromanos sustituidos y métodos para su uso
AR108011A1 (es) Moduladores receptores de estrógenos
AR103252A1 (es) Compuestos de quinazolina
AR102948A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3
AR092288A1 (es) Ligandos del receptor ep1
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR098912A1 (es) Inhibidores de syk
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR088328A1 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR103833A1 (es) Compuestos bicíclicos de sulfonamida cetona
AR090670A1 (es) Compuestos herbicidas
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
AR105991A1 (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR086636A1 (es) Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen
AR098522A1 (es) Compuesto de triazolo-piridina
AR096709A1 (es) Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv)

Legal Events

Date Code Title Description
FB Suspension of granting procedure